Please select the option that best describes you:
Topics:
Allergy & Immunology • Urticaria/Angioedema
Are you increasing the dose and/or frequency of Xolair administration if patients have failed standard dosing for CSU?
Two new drugs have been approved in the past year, but they are not necessarily superior to Xolair for CSU, particularly in refractory cases. Cyclosporine is an option, but side effects are a significant concern.
Answer from: at Community Practice
The data with omalizumab is clear that updosing is safe and effective. Dupilumab, omalizumab and remibrutinib are all about equally effective (about 60%), but updosing omalizumab to 300 every 2 weeks and even to 600 every 2 weeks gives a 60% benefit to the 40% that fail 300 a month
Sign In or Register to read more